GRAIL, Inc. (GRAL) Discusses PATHFINDER 2 Study Results and Clinical Program in Multi-Cancer Early Detection Transcript

Group 1 - The call discusses detailed results from the PATHFINDER 2 study presented at ESMO [2] - Key executives present on the call include the CEO, CFO, and Presidents of International Business and Biopharma [2] - The company intends to make forward-looking statements based on current expectations [3] Group 2 - Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially [4] - The company does not assume any obligation to update forward-looking statements based on currently available information [4]